Author + information
- Received February 6, 2009
- Accepted April 15, 2009
- Published online June 30, 2009.
- David B. Badesch, MD⁎,⁎ (, )
- Hunter C. Champion, MD, PhD†,
- Miguel Angel Gomez Sanchez, MD‡,
- Marius M. Hoeper, MD§,
- James E. Loyd, MD∥,
- Alessandra Manes, MD, PhD¶,
- Michael McGoon, MD#,
- Robert Naeije, MD, PhD⁎⁎,
- Horst Olschewski, MD††,
- Ronald J. Oudiz, MD‡‡ and
- Adam Torbicki, MD, PhD§§
- ↵⁎Reprint requests and correspondence:
Dr. David B. Badesch, Divisions of Pulmonary Sciences and Critical Care Medicine, Pulmonary Hypertension Center, University of Colorado Denver, Leprino Building, Room 536 or Box 957, 12401 East 17th Avenue, Aurora, Colorado 80045
The diagnosis and assessment of pulmonary arterial hypertension is a rapidly evolving area, with changes occurring in the definition of the disease, screening and diagnostic techniques, and staging and follow-up assessment. The definition of pulmonary hypertension has been simplified, and is now based on currently available evidence. There has been substantial progress in advancing the imaging techniques and biomarkers used to screen patients for the disease and to follow up their response to therapy. The importance of accurate assessment of right ventricular function in following up the clinical course and response to therapy is more fully appreciated. As new therapies are developed for pulmonary arterial hypertension, screening, prompt diagnosis, and accurate assessment of disease severity become increasingly important. A clear definition of pulmonary hypertension and the development of a rational approach to diagnostic assessment and follow-up using both conventional and new tools will be essential to deriving maximal benefit from our expanding therapeutic armamentarium.
Please see the end of this article for each author's conflict of interest information.
- Received February 6, 2009.
- Accepted April 15, 2009.
- American College of Cardiology Foundation